Skip to content
The GMP Insider cover art

All episodes

The GMP Insider, 81 episodes.

#
Title
1

Environmental Monitoring: Alert vs Action Limits & Trending

2

ICH Q9(R1) Quality Risk Management: What's Actually New

3

Change Control Management: What Gets Companies in Trouble

4

Contamination Control Strategy (CCS) Under EU GMP Annex 1

5

Deviation Investigation & Root Cause Analysis: 5 Whys Done Right

6

How to Respond to an FDA 483 (and Warning Letter) in 15 Working Days

7

FDA Inspection Readiness 2026: The New Cross-System Inspection Model

8

Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

9

Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained

10

OOS Investigation Explained: Phase 1 vs Phase 2 (21 CFR 211.192)

11

ALCOA+ Explained: The 9 Data Integrity Principles FDA Actually Cites

12

Top 10 FDA 483 Observations in 2026 (and How to Avoid Each One)

13

Quality Debt: The Hidden Liability Inside Pharmaceutical Quality Systems

14

The Hidden Cost of Poor Quality: The Business Impact Beyond Recalls

15

Why CAPA Doesn't Fix Culture: Symptoms vs Systems

16

Compliance vs Effectiveness: Is Your Quality System Healthy?

17

When a Green Dashboard Lies: Signals Your Metrics Miss

18

When Quality Has to Say NO: Tough QA Decisions in Pharma

19

AI Governance in Pharma: Ethics by Design for Quality Leaders

20

Big Pharma vs Small Pharma: Where Quality Culture Thrives

21

The Human Side of Pharma Quality: Quality Is Love in Action

22

QA Leadership: Making Difficult Quality Decisions with Confidence

23

The Most Dangerous Day in Quality: When Questions Stop

24

Beyond CAPA Closure: The QA Judgment That Gets You Promoted

25

The One Lesson Nobody Teaches You in QA

26

Quality by Character: Confidence Through Leadership

27

Quality by Service: Patients, Not Auditors

28

Quality by Purpose: Why You Chose Pharma QA

29

Quality by Trust: Why Patients Trust Pharma QA

30

Quality by Humility: What Every Deviation Teaches QA

31

Quality by Ownership: Quality Is Everyone's Responsibility

32

Quality by Integrity: Doing Right When Nobody Is Watching

33

Quality by Curiosity: Better Questions in Pharma QA

34

Quality by Courage: Speaking Up Protects Patients

35

WE CARE: The Heart of Pharmaceutical Quality

36

Quality by Emotion: The Missing Piece in Pharma QA

37

Data Integrity in Pharma: It Starts Before Data Is Created

38

FDA Inspection Readiness: A Daily Habit, Not a Project

39

AI Governance in Pharma: The Next Big Challenge for QA

40

Weak CAPAs: The Hidden Cost of Closing Without Fixing

41

Quality by Design vs Inspection: What Works in Pharma QA

42

WE DO: The Quality Mindset That Protects Patients

43

Every NO Gets You Closer to YES: A QA Mindset for Pharma

44

AI in Pharma QA: Why Trust Matters More Than Technology

45

QA Career Growth: Stop Sabotaging Your Potential in Pharma

46

Focused Work in Pharma QA: Your Competitive Advantage

47

Fixed vs Growth Mindset in Pharma Quality

48

Why Quality Failures Never Happen Overnight in Pharma

49

Deep Work in Pharma QA: Focus That Improves Quality Systems

50

Quality Is Not a Department: The Bigger Picture in Pharma

51

QA Mistakes That Keep Weak Quality Systems Alive

52

Risk Management in Pharma: Lessons from Artemis II

53

The LISTEN Model: Better Thinking for Pharma QA

54

"Retraining" Is the Most Overused CAPA in Pharma — Here's Why

55

Why People Stay Silent in Weak Quality Cultures

56

"We've Always Done It This Way": Pharma's Most Dangerous Phrase

57

Activity vs Effectiveness: What FDA Really Wants to See

58

"Human Error" Is Not a Root Cause: QA Investigation Mistake

59

How FDA Inspects Biologics: Risk-Based GMP Explained

60

AI Meets FDA: Why Credibility Beats Capability in Pharma

61

FDA 483 Response Guide: What to Do After an Inspection

62

Process Optimization in Pharma: Lessons from Ford v Ferrari

63

Continuous Improvement in Pharma: Lessons from The Martian

64

AI Adoption in Pharma: A Quality Leader's Guide

65

The Architecture of Trust: AI Governance in Pharma

66

Deviations & Root Cause: Lessons from Apollo 13

67

Clinical QA Explained: Building Trust in Trial Data

68

Pharmacovigilance Quality: Guardian of Patient Safety

69

6 Skills Every New Pharma QA Professional Needs

70

Clinical QA vs Commercial QA vs PV QA: Can You Switch?

71

Clinical QA vs Commercial QA vs PV QA Roles Explained

72

Stop Asking "Is It Compliant?" Ask "Is It Under Control?"

73

Data Integrity in Pharma: System Design, Not Documentation

74

Trend Analysis in Pharma QA: Preventing FDA Findings

75

Compliance Drift: Why Leadership Owns Quality Failures

76

Training vs Compliance: What FDA Really Looks For

77

Deviation Investigation: Why Blaming People Fails GMP

78

FDA Inspection Readiness: Stop Treating It Like a Project

79

Quality as the Architecture of Risk Management

80

Data Integrity in GMP: From Trust to System Control

81

Root Cause Analysis Explained Simply (Mickey Mouse Method)